9 participating centres performed both a 1-stage and a Chromogenic FVIII assay. Result data was collected from 78 centres for a FVIII assay on all samples, with 56 centres performing a 1-stage FVIII assay and 22 centres performing a Chromogenic FVIII assay.

Participants were invited to perform a FVIII assay on each of the four samples using testing methods in regular routine use in their laboratory. Samples S19:04 and S19.05 were constructed by ‘spiking’ FVIII deficient plasma, from a severe haemophilia A donor, with Elocta-Sample S19.04 at a level similar to a patient trough level and Sample S19:05 at a level similar to a patient post treatment level. S19:03 was from a patient with severe Haemophilia A patient, treated with 2000 iu/kg Elocta 15 minutes prior to sample collection. Sample S19:02 was from a patient with severe Haemophilia A treated with Elocta, but prior to sample collection was at a treatment trough level. In a supplementary UK NEQAS BC exercise 4 lyophilised samples containing Elocta were distributed to 81 participating centres. Several different laboratory assay methods can be used to monitor Elocta in patient plasma samples. WalkerĮlocta ® is an Fc Fusion Protein classified as an extended half-life (EHL) drug for the management of patients with Haemophilia A. POSTER ABSTRACTS P001 | One stage and chromogenic FVIII assay results at trough levels: A UK national external quality assessment scheme for blood coagulation (UK NEQAS BC) exerciseĪ.

Rebel inc escalation 0.5.5 trainer